This is Part 2 of High-Risk HR-Positive, HER2-Negative Early-Stage Breast Cancer: Bridging Evidence, Risk Identification, and Real-World Practice, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.

 

In this video, Sara Tolaney, MD, MPH, FASCO, Erica Mayer, MD, MPH, FASCO, and Elahe Salehi, DNP, ANP-BC, discuss the management of high-risk hormone receptor–positive early-stage breast cancer with germline BRCA mutations. They review the case of a 42-year-old premenopausal woman with a 5.2-cm, grade 2 invasive ductal carcinoma and two positive lymph nodes. Her Oncotype Recurrence Score is 21, but she has a high disease burden.

 

The faculty highlight how high disease burden and germline mutation status influence treatment intensity, the rationale for incorporating ovarian function suppression in premenopausal patients, considerations for sequencing targeted agents such as PARP inhibitors and CDK4/6 inhibitors, and strategies for monitoring and managing related side effects.